ZBTB17 (MIZ1) Is Important for the Cardiac Stress Response and a Novel Candidate Gene for Cardiomyopathy and Heart Failure by Buyandelger, Byambajav et al.








ZBTB17 (MIZ1) Is Important for the Cardiac Stress Response and a Novel
Candidate Gene for Cardiomyopathy and Heart Failure
Buyandelger, Byambajav ; Mansfield, Catherine ; Kostin, Sawa ; et al
Abstract: BACKGROUND Mutations in sarcomeric and cytoskeletal proteins are a major cause of hered-
itary cardiomyopathies, but our knowledge remains incomplete as to how the genetic defects execute their
effects. METHODS AND RESULTS We used cysteine and glycine-rich protein 3, a known cardiomy-
opathy gene, in a yeast 2-hybrid screen and identified zinc-finger and BTB domain-containing protein 17
(ZBTB17) as a novel interacting partner. ZBTB17 is a transcription factor that contains the peak asso-
ciation signal (rs10927875) at the replicated 1p36 cardiomyopathy locus. ZBTB17 expression protected
cardiac myocytes from apoptosis in vitro and in a mouse model with cardiac myocyte-specific deletion of
Zbtb17, which develops cardiomyopathy and fibrosis after biomechanical stress. ZBTB17 also regulated
cardiac myocyte hypertrophy in vitro and in vivo in a calcineurin-dependent manner. CONCLUSIONS
We revealed new functions for ZBTB17 in the heart, a transcription factor that may play a role as a
novel cardiomyopathy gene.
DOI: https://doi.org/10.1161/CIRCGENETICS.113.000690





Buyandelger, Byambajav; Mansfield, Catherine; Kostin, Sawa; et al (2015). ZBTB17 (MIZ1) Is Important
for the Cardiac Stress Response and a Novel Candidate Gene for Cardiomyopathy and Heart Failure.
Circulation. Cardiovascular Genetics, 8(5):643-652.
DOI: https://doi.org/10.1161/CIRCGENETICS.113.000690
643
Mutations in >50 genes, mostly encoding sarcomeric and Z disc proteins, cause hypertrophic cardiomyopathy 
(HCM) and dilated cardiomyopathy (DCM) that lead to heart 
failure.1 Genetic variation in a Z disc gene can cause various 
forms of cardiomyopathies such as HCM or DCM perhaps 
because of pleiotropic effects on survival and hypertrophic 
pathways.2 The muscle LIM protein (cysteine and glycine-
rich protein 3 [CSRP3]) is a Z disc protein involved in car-
diac mechanosensation that is important for myocyte-specific 
survival pathways through interactions with other Z disc pro-
teins.3–5 CSRP3 mutations have been found in both HCM and 
DCM patients,3,4,6 and we used protein–protein interaction 
studies to identify new CSRP3-interacting partners that may 
be important for cardiac myocyte survival or cardiomyopathy.
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Methods
All primers and antibodies used are listed in Tables I to III in the 
Data Supplement. Tissue culture experiments were performed using 
primary neonatal and adult rat cardiac myocytes, and animal experi-
ments were performed using conditional knockout (cKO-Zbtb17), 
overexpressing transgenic (TG-ZBTB17) and double-transgenic 
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(TG-ZBTB17/KO-Ppp3cb) protein phosphatase 3, catalytic subunit, 
β isozyme (calcineurin Aβ, Ppp3cb) animals.
The procedures in animal studies have been followed in accor-
dance with institutional guidelines. Human studies have been ap-
proved by an institutional review committee, and that the subjects 
gave informed consent.
Yeast 2-hybrid, Western blot, quantitative real-time polymerase 
chain reaction, and other assays were performed as described else-
where.3–5,7 Statistical evaluations were performed by nonparametric 
Mann–Whitney U tests and unpaired Student t tests (more details are 
available in the Data Supplement).
Results
CSRP3 Interacts With ZBTB17
Yeast 2-hybrid screens using CSRP3 as bait3 classified 
α-actinin and telethonin as CSRP3-interacting proteins that 
are important determinants of cardiac function5,8 and also 
identified ZBTB17 (Figure 1A). ZBTB17 is a member of the 
poxvirus and zinc-finger (POZ or BTB) domain/zinc-finger 
transcription factor family with no previously described role 
in the heart.9 We confirmed the CSRP3–ZBTB17 interaction 
by coimmunoprecipitation in vivo (Figure 1B), cross-linking 
of recombinant proteins (Figure 1C), and immunohistochem-
istry studies (Figure 1D; Figure I in the Data Supplement). 
These data identify ZBTB17 as a novel CSRP3-interacting 
protein.
Analysis of a Human ZBTB17 Variant (T106M)
ZBTB17 is encoded on human chromosome 1 at the repli-
cated 1p36 cardiomyopathy locus.10–12 The peak DCM asso-
ciation at this locus (rs10927875; P=1.3×10−7)12 is located in 
intron 2 of ZBTB17, with further evidence of association of 
this single nucleotide polymorphism with DCM in Chinese 
population.12,13
Considering rare polymorphisms (allele frequency 
<0.1%; population prevalence of cardiomyopathies 
≈1:5001), we identified a p.T106M variant in the Exome 
Variant Server. The p.T106M variant could not be stably 
expressed in cardiac myocytes (Figure 2A), bound poorly to 
CSRP3 (Figure 2B), caused structural abnormalities to the 
POZ domain (Figure 2C and 2D), and may represent a rare 
haploinsufficient polymorphism. Together, these data point 
to ZBTB17 as a possible disease gene at the 1p36 cardio-
myopathy locus and suggest a role for a transcription factor 
in heart failure, as recently shown for left ventricular non 
compaction cardiomyopathy.14
Analysis of ZBTB17 Function In Vitro
To study function in vitro, we overexpressed ZBTB17 in car-
diac myocytes and found that it induced hypertrophy (Fig-
ure 3A and 3B; Figure IIA in the Data Supplement). CSRP3 
and other CSRP3-interacting proteins have important roles 
in cardiac myocyte survival, and this was also observed for 
ZBTB17 (Figure 3C; Figure IIB in the Data Supplement). 
Calcineurin activity is of central importance for prohyper-
trophic signaling and myocyte survival,15,16 and in both the 
hypertrophy and the cell death experiments inhibition of 
calcineurin attenuated the effects of ZBTB17, suggesting 
an interaction (Figure 3A and 3C). Hence, ZBTB17 regu-
lates cardiac hypertrophy and cell survival, a recognized 
dual-property of genes that are of central importance for car-
diac myocyte biology.15–18
Analysis of ZBTB17 Function In Vivo
Mice with global deletion of Zbtb17 die because of a gastru-
lation defect.19 Therefore, we crossed floxed Zbtb17 mice20 
with the MLC2v Cre deleter line21 to test Zbtb17 gene func-
tion in cardiac myocyte–specific cKO (Figure 3A–3D in the 
Data Supplement). cKO mice were viable and, in the absence 
of a spontaneous functional cardiac phenotype, we used the 
established model of transverse aortic constriction (TAC)5 to 
unveil potential gene effects. After TAC, the left ventricles 
of cKO mice became dilated and exhibited impaired contrac-
tile performance, which are the cardinal features of DCM 
(Table 1). When compared with controls, failing cKO hearts 
had higher apoptotic events (8.5-fold; P<0.001), increased 
activated caspase 3 (6.3-fold; P<0.001), and marked replace-
ment fibrosis (Figure 4A; Figure IIIE and Table II in the Data 
Supplement). These data show that Zbtb17 modulates bio-
mechanical stress–induced apoptosis and interstitial fibro-
sis in vivo, which are important in the pathobiology of both 
HCM and DCM.
To begin to understand the molecular mechanisms by 
which ZBTB17 regulates cardiac myocyte survival, based 
on the functions of ZBTB17 in other tissues,19 we com-
bined our microarray data with apoptosis-specific gene 
expression array analysis (quantitative real-time polymerase 
chain reaction based, n=84) in cKO.TAC and control.TAC 
mouse hearts. We used Gene Set Enrichment Analysis22 to 
test whether differentially expressed genes by genome-wide 
microarray analysis were significantly enriched in the set of 
differentially expressed genes detected by apoptosis-specific 
quantitative real-time polymerase chain reaction array analy-
sis and found significant concordance for a set of 8 genes 
(P<0.05, false discovery rate, <1%; Table 2). Among these, 
the proapoptotic genes were consistently upregulated in cKO, 
whereas the antiapoptotic genes, Nol3 and Tnfrsf1a, were 
downregulated in cKO hearts after biomechanical stress, 
supporting a role for Zbtb17 in the regulation of apoptosis. 
Six of 8 differentially expressed genes were also detected by 
ChIP-chip analysis to have binding sites (Table 2). Hence 
ZBTB17 regulates a transcriptional program that protects 
cells against apoptosis.
In addition, ZBTB17 overexpression drives hypertrophy 
in vitro (Figure 3). To examine further the effects of ZBTB17 
on hypertrophy we overexpressed ZBTB17 in mice using a 
cardiac myocyte–specific promoter23 (Figure IV in the Data 
Supplement ). Transgenic mice (TG-ZBTB17) exhibited 
spontaneous cardiac hypertrophy with enlarged cardiac myo-
cytes and increased Nppa expression (Table I in the Data 
Supplement ; Figure 4B and 4C). In vitro experiments sug-
gested a link between ZBTB17 and calcineurin, and ChIP-
chip data showed binding of ZBTB17 to the calcineurin Aβ 
(Ppp3cb) promoter that we confirmed by ChIP quantita-
tive real-time polymerase chain reaction and reporter assays 
(Figure 4D and 4E). There was increased expression of Ppp3cb 
and Nfatc2 in TG-ZBTB17 hearts and decreased expression 
in cKO (Figure 4F; Figure VA in the Data Supplement). We 
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Figure 1. A, Analysis of the interaction between cysteine and glycine-rich protein 3 (CSRP3) and zinc-finger and BTB domain-containing 
protein 17 (ZBTB17) by yeast 2-hybrid assays. No interaction occurs between proteins when the ZBTB17-POZ domain is deleted (lower right 
quadrant). A total of 106 clones were screened, and 650 positive clones were identified,3 one of which encoded the 5′ sequence of Zbtb17. 
B, Immunoprecipitation of ZBTB17 from heart lysates results in the coprecipitation of CSRP3. Input indicates mouse heart extract, a Csrp3 
antibody (sc-30274; Santa Cruz Biotechnology) has been used for immunoprecipitation, and a well-characterized Zbtb17 (Santa Cruz H-190; 
sc 22837) antibody has been used to detect the protein. No antibody or an unrelated anti-Kir2.1 antibody served as negative controls.  
C, Cross-linking experiments of recombinant proteins confirm binding between ZBTB17 and CSRP3. Top, With increasing concentration 
of cross-linking reagent, the individual components decrease, whereas a large complex emerges. The complex contains multiple copies 
of each protein reflecting the oligomeric nature of the individual components. Bottom left, Positive control showing cross-linking between 
CSRP3 and Telethonin (TCAP), a known interaction. Bottom right, Negative controls: we attempted to cross-link CSRP3 separately with 
2 different proteins that have no documented association but are known to cross-link well to their binding proteins. These were small 
glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) and HLA-B associated transcript 3 (BAT3). As expected, increasing 
cross-linking reagents showed no binding between CSRP3 and the negative control proteins, but only the usual CSRP3 oligomers indicated 
with stars. D, Colocalization of ZBTB17 and CSRP3 in the nuclei of human cardiac myocytes. Arrows indicate typical cardiac myocyte 
nuclei that are positive for both ZBTB17 and CSRP3. Lower left, Three-dimensional image of the boxed region (left middle). Lower right, 
Three-dimensional colocalized color intensity image of ZBTB17 with CSRP3: mean percentage of nuclear ZBTB17 colocalized with nuclear 
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background that prevented cardiac myocyte hypertrophy and 
decreased Nppa expression, confirming the interaction of 
ZBTB17 with the calcineurin pathway (Figure 4B; Table I in 
the Data Supplement ).
Discussion
CSRP3 mutations cause heart failure in various animal mod-
els4,24 and have been identified in various patients affected 
by DCM3,25 or HCM.26–28 Although many cardiomyopathy 
and heart failure models have been developed, the molecular 
mechanisms that link sarcomeric and Z disc proteins to these 
phenotypes remain not well understood. Here, we show 
that CSRP3 interacts with ZBTB17 and provide the first 
detailed analysis of this transcription factor in the cardio-
vascular system. In particular, we demonstrate that ZBTB17 
causes cardiac myocyte hypertrophy and is essential for cell 
survival. The extent of hypertrophy in cardiac myocytes is 
comparable with the effects seen with trophic signals includ-
ing mitogenic serum in these postmitotic cells.29,30 To date, 
ZBTB17 is the only known transcription factor to interact 
with CSRP3 and to be expressed in cardiac myocytes.31 The 
effects of ZBTB17 on hypertrophy and survival are not only 
restricted to the in vitro situation but also observed in geneti-
cally altered animals under in vivo conditions. Interestingly, 
ZBTB17-overexpressing transgenic animals did not develop 
heart failure because of massive increase in apoptosis as fre-
quently seen in other genetically altered mouse models.32–35
The combination of ChIP-chip, whole-gene expression, 
and apoptosis array data clearly point to an important role of 
ZBTB17 in orchestrating a cardioprotective gene expression 
Figure 2. A, Analysis of wild-type (WT)- and T106M–zinc-finger and BTB domain-containing protein 17 (ZBTB17) proteins via adeno-
viral overexpression in neonatal rat cardiac myocytes. Although WT-ZBTB17 protein is readily detectable, ZBTB17:p.T106M was not 
and is most likely unstable in eukaryotic cells. B, Interaction of T106M-ZBTB17 with cysteine and glycine-rich protein 3 (CSRP3) as 
studied via cross-link interaction. CSRP3 interacts with WT-ZBTB17 (left), but interacts less well with T106M-ZBTB17 (right).  
C, NMR1H-15 N HSQC spectrum of WT (red) and T106M (black) ZBTB17-POZ domain with pertinent residues assigned based on pre-
dicted chemical shift. The mutation causes significant structural disruption to the POZ domain. D, The available ZBTB17-POZ struc-
ture was used to model the T106M mutation. Fifty nanoseconds of simulation of the WT and the T106M structures that have been 
run as the full quadrameric structures as in the PDB 2Q81. Red indicates the native and yellow the mutant ZBTB17, spheres repre-
sent the T and M residues. It can be clearly seen that the structures of the α-6, where the mutation is located, have changed. Also 
the simulations reveal that there is a much higher level of structural mobility for the mutant case. The mutation causes significant 
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program. This is indicated by the fact that proapoptotic 
genes were consistently upregulated, whereas antiapoptotic 
genes were downregulated in cKO hearts after biomechani-
cal stress (Table 3).
We also show that ZBTB17 targets various calcineurin/
NFAT genes and activates this pathway. This notion is sup-
ported by our whole-gene expression analysis, ChIP-chip 
assays, analysis of the calcineurin/NFAT pathway activation, 
promoter assays, and by the significant loss of hypertrophy 
when TG-ZBTB17 animals are crossed into the calcineurin 
Aβ–deficient background (Figures 3 and 4D and 4E). These 
data are also supported by our finding of enhanced calcineu-
rin Aβ and Nfatc2 mRNAs in hearts of ZBTB17 transgenic 
animals and decreased calcineurin Aβ and Nfatc2 mRNAs in 
hearts of Zbtb17 cKO animals after TAC (Figure 4F; Figure 
VA in the Data Supplement).
CSRP3 translocates into the nucleus on TAC36 and is 
essential for the adaptation of cardiac myocytes to biomechan-
ical stress.37 CSRP3, like telethonin, is primarily expressed in 
muscle tissues. By interacting with ZBTB17, CSRP3 plays a 
Figure 3. A, Analysis of zinc-finger and BTB domain-containing protein 17 (ZBTB17) overexpression in neonatal rat cardiac myo-
cytes (NRCMs) as determined by impedance measurements. Scatter dot plot represents cell index values after 24 h (n=10, experi-
ments done in duplicate). Dotted lines indicate cell indices in calcineurin inhibition experiments (Cyclosporin A [CsA]: 0.2 µmol/L; 
n=4; Mann–Whitney U test was used for the comparison of groups, **P<0.01). B, Representative images of NRCMs with and without 
ZBTB17 adenoviral gene transfer. C, Effects of ZBTB17 overexpression on doxorubicin (DOX, 1 µmol/L)–induced cell death (n=4). 
Dotted lines indicate data from calcineurin inhibition experiments (CsA: 0.2 µmol/L; n=4; Mann–Whitney U test was used for the com-
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role in the initiation of myocyte-specific survival pathways or 
mechanoptosis (mechanosensitive types of cell death5). This 
notion is supported by the fact that Csrp3-deficient hearts 
exhibit increased rates of apoptosis,38 hence the interaction of 
CSRP3 with ZBTB17 can also be described as a form of Z 
disc transcriptional coupling.39
Calcineurin/NFAT signaling is an important mediator 
of cardiac hypertrophy,40,41 and this pathway is also known 
to exert cardioprotective effects by avoiding apoptosis dur-
ing ischemia reperfusion,15 which emphasizes the effects of 
ZBTB17 on cell survival.
CSRP3 directly interacts with calcineurin and is required 
for its activation,42 thus by interacting with ZBTB17; CSRP3 
introduces an additional level of control, which ensures an 
intermediate level of calcineurin/NFAT activation (Figure 4G). 
For a long time, c-myc is known to be induced during TAC,43 
but its downstream effects in cardiac myocytes remained elu-
sive. However, c-myc is known to inhibit ZBTB1744 and there-
fore may have adverse effects on survival and hypertrophy in 
cardiac myocytes. Interestingly, CSRP3 interacts with the 
aminoterminal POZ domain, which is predicted to interfere 
with ZBTB17 tetramerization.
An additional layer of complexity is added by the fact that 
ZBTB17 can be phosphorylated at position S428 by the Akt 
kinase, which is another important mediator of hypertrophy.45 
This post-translational modification enables the interaction 
of ZBTB17 with 14-3-3 ŋ and leads to its inactivation, thus 
avoiding prolonged activation of ZBTB17, which can also 
have adverse effects.46
In the Exome Variant Server database, there are 10 
T106M variants annotated out of at least 13 006 alleles of 
European-American and Afro-American origin combined. 
The Exome Variant Server does not provide data on indi-
vidual phenotypes, but the frequency for this variant is 
certainly low and a disease causing or at least modifying 
role cannot be excluded. Nevertheless, a 2-hit hypothesis 
whereby a structural perturbation combines with a defect in 
a ZBTB17-mediated cell survival pathway could also lead 
to heart failure.
As a result, we expect this variant to impair calcineu-
rin-dependent hypertrophy and being unable to efficiently 
protect cardiac myocytes from apoptosis. However, this 
variant may also have specific effects on remodeling and 
hypertrophy47 by specifically affecting protein degradation 
pathways, for example, via the ubiquitin proteasome sys-
tem,48 and aside from affecting its interaction with CSRP3 
(Figure 2B), may specifically interfere with other protein/
protein interactions.
ZBTB17 is a transcription factor that contains the peak 
association signal (rs10927875) at the replicated 1p36 car-
diomyopathy locus. Although other genes in the genomic 
region of ZBTB17, such as HSPB7 and CLCNKA, have been 
suggested as possible candidate genes by genome-wide asso-
ciation study,10,49 ZBTB17 might well be another novel DCM-
associated gene. However, except for this report, the effects 
of ZBTB17 on the cardiovascular system have never been 
analyzed before. It is interesting to note that HSPB7, which 
encodes heat shock protein 27, a factor involved in the imme-
diate stress response, CLCNKA, which encodes a K
a
 renal 
chloride channel involved in the regulation of hypo-osmotic 
cell stretch, as well as ZBTB17, are all involved in the cellular 
primary stress response and survival signaling.
At least 50 single genes have been identified as linked to 
familial DCM, some of which encode proteins of the sarco-
mere,50 costamere, Z disc,3,4 and nuclear membrane,51 whereas 
others function as phosphatases and transcriptional activa-
tors (EYA4).1,52 Unfortunately, not much is known about 
how these effects are linked to changes in gene transcription. 
A recent study found profibrotic gene expression profiles in 
HCM mouse models and identified transforming growth fac-
tor beta 1 (TGFβ1) as the initiating event, but the underlying 
transcriptional events remained elusive.53 However, ZBTB17 
may well play a role in these genetic circuits. Defective Z 
disc–mediated survival signaling may also contribute to the 
DCM phenotype observed in patients carrying truncating Titin 
(TTN) mutations.50
In summary, we identify ZBTB17 as a candidate for a 
new cardiomyopathy gene, which may also be important for 
heart failure syndromes in general, and suggest that its pri-
mary function is to protect cardiac myocytes from apoptosis5 
through modulation of both hypertrophic and cell death path-
ways (Figure 4G).
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Functional data obtained via echocardiography 4 weeks after sham (SHAM) and transverse aortic constriction (TAC) operations in Zbtb17 conditional knockout (cKO) 
and control animals. After TAC, cKO hearts enlarge (LVIDd and LVIDs) and decrease in function (FS%; control=flox/flox, Cre− and cKO=flox/flox, Cre+). BW indicates body 
weight; EF, ejection fraction; h/r, left ventricular wall thickness divided by left ventricular radius; HW, heart weight; LVIDd, left ventricular internal diameter in diastole; 
LVIDs, left ventricular internal diameter in systole; LV
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Figure 4. A, Representative micrographs of fibrosis staining of mouse hearts after sham (SHAM) or transverse aortic constriction (TAC) 
procedures and quantification of fibrosis (4 data points per animal, 1 representative experiment of 2 shown; Mann–Whitney test was used 
for the comparison of groups; *P<0.05). B, Analysis of cardiac myocyte cross-sectional area under spontaneous conditions in wild-type 
(WT)-zinc-finger and BTB domain-containing protein 17 (ZBTB17), conditional knockout (cKO)-Zbtb17, transgene (TG)-ZBTB17 (≈150 
cardiac myocytes per animal; n=5 per group, Mann–Whitney U test was used for the comparison of groups, *P<0.05, **P<0.01), and KO-
Ppp3cb, TG-ZBTB17/KO-Ppp3cb (≈150 cardiac myocytes per animal; n=2 per group). C, Upregulation of the prohypertrophic biomarker 
Nppa in TG-ZBTB17 hearts (n=2 per group, experiments done in duplicate). D, Chromatin immunoprecipitation microarray quantita-
tive real-time polymerase chain reaction analysis of Zbtb17 binding to the Ppp3cb promoter in vivo (1 representative experiment of 2 
shown, Mann–Whitney U test was used for the comparison of groups, *P<0.05). E, Luciferase reporter assay of ZBTB17 activation of the 
Ppp3cb promoter via transient transfection (n=3–4 per group, Mann–Whitney U test was used for the comparison of groups, *P<0.05). 
F, Increased Ppp3cb and Nfatc2 mRNA expression levels in TG-ZBTB17 (1 representative experiment of 2 shown, Mann–Whitney U 
test was used for the comparison of groups, *P<0.05). G, ZBTB17 is important for the adaptation of cardiac myocytes to biomechanical 
stress. Loss of ZBTB17 is associated with an increase in cardiac myocyte apoptosis and heart failure, whereas overexpression leads to 
activation of the calcineurin/nuclear factor of activated T-cell (NFAT) pathway and cardiac myocyte hypertrophy. MLP indicates muscle 
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Table 2. Summarized Expression Profiles and Zbtb17 Binding Sites of Target Genes Involved in Cardiac Myocyte–Specific 
Programmed Cell Death in cKO Animals (n=6 Per Group)
Apoptosis RT2 Profiler PCR Array data (SA Biosciences)
Whole-transcript array  
data (Affymetrix Microarray) GSEA ChIP-Chip




FDR Value of 
Binding
Casp1 0.0034 0.006 1.76 0.028 0.0193 0.0386 2 + 0.00214
Casp2 0.0098 0.0215 2.2 0.002 0.0341 0.0431 1.26 + 0.02509
Casp3 0.003 0.0044 1.5 0.062 0.0223 0.0583 2.61 + 0.05001
Casp9 0.0112 0.0207 1.86 0.057 −0.0216 0.0107 2.5 + 0.01765
Traf3 0.0044 0.0071 1.61 0.008 −0.057 −0.0105 1.82 + 0.04486
Casp12 0.0008 0.0015 1.84 0.085 0.069 0.1771 2.57 … 0.02754
Nol3 0.0282 0.0198 0.7 0.008 0.1438 0.0985 0.68 … NBS
Tnfrsf1a 0.0157 0.0092 0.59 0.054 0.1712 −0.0728 −0.43 … NBS
Directional change of genes is consistent with the antiapoptotic role of endogenous Zbtb17. cKO indicates conditional knockout; GSEA, Gene Set Enrichment Analysis; 
PCR, polymerase chain reaction; NBS, no ZBTB17 binding site; TAC, transverse aortic constriction.




Activated Caspase  
3 (n/1000 Cardiomyocytes) Collagen I (% Tissue Area)
Control.TAC cKO.TAC Control.TAC cKO.TAC Control.TAC cKO.TAC
1 1.04 11.35 3.53 17.73 5.89 10.71
2 1.73 12.55 3.86 21.81 6.63 12.53
3 1.49 9.41 4.01 19.55 7.22 16.24
4 2.38 15.44 3.37 19.92 5.14 11.25
5 0.95 13.87 3.88 25.77 7.73 15.02
6 1.72 8.08 1.85 23.19 6.85 13.09
Mean±SD 1.55±0.5 11.78±2.5* 3.42±0.73 21.32±2.63* 6.57±0.85 13.29±1.98*
cKO indicates conditional knockout; RT2, real-time-2 referring quantitative real-time PCR; TAC, transverse aortic constriction; 
and TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
Student t tests were used for the comparison of groups, data=mean±SD; Control.TAC: flox/flox, Cre−; cKO.TAC: flox/flox, Cre+; 
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CLINICAL PERSPECTIVE
Mutations in >50 genes, mostly encoding sarcomeric and Z disc proteins, are a major cause of hereditary cardiomyopathies. 
However, most likely this list is incomplete, and, probably most importantly, the underlying molecular disease-causing 
mechanisms remain not well defined. Here, we used cysteine and glycine-rich protein 3 (also known as muscle LIM protein), 
a known cardiomyopathy gene, and identified zinc finger and BTB domain-containing protein 17 (ZBTB17) as a novel inter-
acting partner. ZBTB17 is a transcription factor that contains the peak association signal (rs10927875) at the replicated 1p36 
cardiomyopathy locus, identified in various recent genome-wide association studies. Loss of Zbtb17 in cardiac myocytes 
causes apoptosis and heart failure, whereas overexpression of ZBTB17 drives calcineurin/nuclear factor of activated T-cell 
(NFAT)–dependent cardiac myocyte hypertrophy. Here, we provide the first detailed analysis of ZBTB17 in the cardiovas-
cular system and provide evidence for ZBTB17 being a novel cardiomyopathy candidate gene. ZBTB17 functions might be 
exploited for the development of innovative therapies to treat heart failure, an otherwise lethal condition.
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